tucatinib,trastuzumab deruxtecan
seagen,daiichi sankyo,astrazeneca
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'destiny,crc,02', 'tucatinib']
destiny-crc02 data for t-dxd in crc: decent orr: 37.8% lower dose (5.4 mg/kg) is better and less toxic responses seen despite ras mutation if her2 ihc 3+ and after prior her2-targeted tx tucatinib/trastuzumab still my soc. same orr, longer dor and less toxic
#asco23 
GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own